Therapeutic Effect of Laparoscopic Cholecystectomy on Patients with Cholecystolithiasis Complicated with Chronic Cholecystitis and Postoperative Quality of Life

Jie Song,1 Jie Chen,2 and Chunyan Lin1

1Department of General Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China
2Department of Hepatobiliary Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China

Correspondence should be addressed to Chunyan Lin; linshaobengza4051@163.com

Received 22 April 2022; Revised 3 June 2022; Accepted 21 June 2022; Published 21 July 2022

Objective. To assess the treatment outcome and postoperative quality of life of patients with gallbladder stones and chronic cholecystitis after open cholecystectomy and laparoscopic cholecystectomy.

Methods. Between 2018 and 2020, 108 patients with gallbladder stones and chronic cholecystitis treated in our hospital were assessed for eligibility and randomly recruited. They were concurrently assigned (1:1) to receive either open cholecystectomy (control group) or laparoscopic cholecystectomy (study group). Outcome measures include surgical indices, inflammatory response, postoperative complications, and quality of life of patients.

Results. Laparoscopic cholecystectomy was associated with a shorter duration of surgery, intraoperative bleeding, time to first postoperative bowel movement, and postoperative hospital stay versus open cholecystectomy (P < 0.05). The levels of inflammatory factors of all eligible patients were comparable before cholecystectomy (P > 0.05). The patients given laparoscopic cholecystectomy showed lower levels of C-reactive protein (CRP), interleukin (IL)-6, and IL-8 versus those given open cholecystectomy (P < 0.05). Laparoscopic cholecystectomy resulted in a significantly lower incidence of complication (3.56%) versus open cholecystectomy (24.07%) (P < 0.05). All patients had significantly higher physical, psychological, and social function scores after laparoscopic cholecystectomy versus open cholecystectomy (P < 0.05). Conclusion. Laparoscopic cholecystectomy provides better surgical results, mitigates the inflammatory response, lowers the incidence of complications, and improves the quality of life of patients versus open cholecystectomy, so it is worthy of application in clinical treatment.

1. Introduction

Chronic cholecystitis is a chronic inflammatory lesion of the digestive system, which is a chronic inflammation of the gallbladder elicited by various causes such as recurrent acute or subacute cholecystitis or long-standing gallstones [1]. The prevalence of chronic cholecystitis in adults is reported to be 0.78% to 3.91% in China, and the prevalence of gallbladder stones is 2.3% to 6.5% [2]. The prevalence of gallbladder stones is higher in women than in men, and the peak incidence is after the age of 50. As the standard of living of the Chinese people continues to improve, the incidence of chronic cholecystitis is on the rise [3]. Its early clinical symptoms mainly include abdominal pain, belching, vomiting, and other symptoms of hepatogenic dyspepsia [4]. Complications occur most often in acute attacks of cholecystitis and pancreatitis, and about 25% of patients develop bacterial infections, caused by obstruction of the cystic duct or common bile duct, which seriously endanger the health and daily life of the patient. Most patients with chronic cholecystitis are accompanied by gallbladder stones, also known as cholelithiasis [5], a condition in which stones are found in the biliary system, such as the gallbladder or bile ducts, with the typical symptoms of biliary colic. Epidemiological data show that nearly 70% of patients with chronic cholecystitis have gallbladder stones; therefore, the combination of chronic cholecystitis with gallbladder stones has received much attention in recent years, and timely and effective interventions are essential to improve the outcome and prognosis of patients’ lives [6–8].
Oral lithotripsy may be considered in symptomatic patients who are not candidates for surgery and have cholesterol stones assessed by abdominal ultrasonography as having normal gallbladder function and negative radiographs [9]. Ursodeoxycholic acid (UDCA) is currently the only bile acid drug approved by the US FDA for the nonsurgical treatment of gallstones [10]. Patients with chronic cholecystitis often suffer from dyspepsia, and in the early stages of dyspepsia, medications such as azatidine or other pancreatic enzymes can be used to improve the symptoms [11]. Patients with chronic cholecystitis usually do not require antibiotics. However, it is important to use antibiotics appropriately when the patient has a combination of underlying diseases, especially if there is impairment of liver or kidney function [12]. However, when surgery is indicated, surgical removal of the gallbladder is the treatment of choice [13]. Cholecystectomy is the most common procedure in biliary surgery for various acute and chronic cholecystitis, symptomatic gallbladder stones, and gallbladder augmentation lesions, and its long-term outcomes are considered satisfactory in most cases. Cholecystectomy consists of open cholecystectomy and laparoscopic cholecystectomy [14–16]. With advances in medical technology, both surgical procedures are effective in the treatment of patients with gallbladder stones combined with chronic cholecystitis, but comparative analyses of their treatment outcomes and postoperative quality of life are inadequate due to the lack of standardized and universally validated tools [17].

Accordingly, the present study was to assess the treatment outcome and postoperative quality of life of patients with gallbladder stones and chronic cholecystitis after open cholecystectomy and laparoscopic cholecystectomy to provide a reference for clinical surgical alternatives.

2. Materials and Methods

2.1. Research Subjects. Between 2018 and 2020, 108 patients with gallbladder stones and chronic cholecystitis treated in our hospital were assessed for eligibility and randomly recruited. They were concurrently assigned (1:1) to a control group or a study group. The study/research was approved by the Ethics Committee of the Affiliated Hospital of Jiangnan University, No. J29879.

2.2. Inclusion and Exclusion Criteria

2.2.1. Inclusion Criteria

(1) All diagnosed with gallbladder stones and chronic cholecystitis [18]

(2) With consciousness and no combined psychiatric diseases

(3) With no autoimmune system diseases or acute biliary pancreatic diseases

2.2.2. Exclusion Criteria

(1) With cardiac, hepatic, renal, and other important organ insufficiencies

(2) With surgical-related contraindications

(3) With coagulation disorders

2.3. Methods. Patients in both groups were in the supine position. Open cholecystectomy was performed for patients in the control group [19]. After general anesthesia, a 10 cm long incision is made in the right upper abdomen through the rectus abdominis muscle. The abdominal wall is incised into the abdominal cavity in sequence, and the operation is extended with a large “S” shaped hook. The gallbladder is removed in a cisverse fashion, the exudate is aspirated with sterile gauze, a drainage tube is placed in the abdominal wall, the abdominal cavity is cleaned, and the incision is closed layer by layer. Postoperative gastrointestinal decompression and anti-infective treatments were given. The patients in the study group underwent laparoscopic cholecystectomy [7]. The patient was given intravenous general anesthesia with tracheal intubation preoperatively, and a 1 cm curved incision was made below the umbilicus after the routine establishment of a CO2 pneumoperitoneum, followed by the placement of a 10 mm Trocar to examine the abdominal cavity condition. A 1 cm incision was made 4 cm below the glabella as the main operating port, where a 10 mm Trocar was placed. A 5 mm Trocar was placed 2 cm below the right rib in the anterior axillary line and 2 cm below the rib in the right midclavicular line to establish a secondary operating port, and the gallbladder and the cystic duct were fully exposed and separated. The gallbladder was resected under laparoscopic assistance and removed through the main operating port. The surgical area was irrigated, and the incision was sutured sequentially. Postoperatively, routine gastrointestinal decompression and anti-infective treatment were given.

2.4. Outcome Measures

① Surgical indices: the surgical conditions (including the duration of surgery, intraoperative bleeding, time to first postoperative bowel movement, and postoperative hospital stay) of the two groups were recorded and compared.

② Inflammatory factors: fasting venous blood was collected before and 2 d after surgery in the two groups, respectively, to separate serum. Serum C-reactive protein (CRP) was determined by the scattering turbidimetric method, and interleukin-6 (IL-6), and interleukin-8 (IL-8) were determined by the enzyme-linked immunosorbent assay (EusA).

③ Complications: the occurrence of surgical complications (including incisional infection, bile duct bleeding, abdominal infection, pulmonary infection, and intrahepatic cholestasis) was recorded separately in both groups to calculate the incidence. Complication rate = number of people with complications/total number of people × 100%.

④ Quality of life [20]: the quality of life of the two groups was analysed by comparing the scores of the 3
domains of physical function, psychological function, and social function of the patients. Each dimension had 5 assessment factors, and the scores were proportional to the quality of life.

2.5. Statistical Analysis. SPSS 22.0 software was used for data analyses. The count data were expressed as \( n \) (%) and processed using the chi-square test, and the measurement data were expressed as \( \bar{x} \pm s \) and processed using the \( t \)-test. Differences were considered statistically significant at \( P < 0.05 \).

3. Results

3.1. Baseline Information. The baseline characteristics of the patients in the study group (28 males and 26 females, aged 58–77 years, mean age of (59.23 ± 3.78) years, duration of disease of [1–5] years, mean duration of disease of (3.02 ± 0.82) years, the stone diameter of (2.87–18.67) mm, and mean diameter of (5.23 ± 2.17) mm) were comparable with those in the control group (27 males and 27 females, aged 55–79 years, mean age of (59.18 ± 4.05) years, duration of disease of [1–5] years, mean duration of disease of (3.17 ± 5.02) years, the stone diameter of (3.21 ± 7.23) cm, and mean diameter of (5.48 ± 1.99 mm) \( (P > 0.05) \) (Table 1).

3.2. Surgical Conditions. Compared to open cholecystectomy (120.98 ± 31.65, 119.16 ± 14.41), laparoscopic cholecystectomy was associated with shorter operative time, intraoperative bleeding, time to first postoperative bowel movement, and postoperative hospital stay \( (88.25 ± 25.63, 75.83 ± 7.23, 37.85 ± 3.17, 5.02 ± 3.21) ± 14.41, 58.25 ± 5.21, 8.74 ± 3.11) \( (P < 0.05) \) (Table 2).

3.3. Inflammatory Response. All eligible patients had comparable levels of inflammatory factors prior to cholecystectomy \( (P > 0.05) \). CRP, IL-6, and IL-8 levels were lower in laparoscopic cholecystectomy patients \( (16.18 ± 3.21, 55.74 ± 6.18, 22.57 ± 5.67) \) than in open cholecystectomy patients \( (26.24 ± 2.87, 64.87 ± 4.96, 41.68 ± 5.21) \) \( (P < 0.05) \) (Table 3).

3.4. Complications. Compared with open cholecystectomy, laparoscopic cholecystectomy had a significantly lower complication rate (3.56%) (1 (1.85%) incisional infection, 1 (1.85%) bile duct haemorrhage, and 1 (1.85%) intrahepatic cholestasis) and (24.07%) (5 (9.25%) incisional infections, 2 (3.71%) bile duct haemorrhages, 1 (1.85%) abdominal infection) cases, 1 (1.85%) pulmonary infection, 4 (7.41%) cases of intrahepatic cholestasis \( (P < 0.05) \) (Table 4).

3.5. Quality of Life. Patients’ physical, psychological, and social functioning scores were significantly higher after laparoscopic cholecystectomy \( (86.23 ± 5.96, 87.45 ± 5.12, 83.17 ± 4.91) \) than after open cholecystectomy \( (73.84 ± 5.17, 76.77 ± 4.84, 73.65 ± 5.95) \) \( (P < 0.05) \) (Table 5).

4. Discussion

Patients with gallbladder disease usually present with a long duration, acute and rapid progression, and are highly susceptible to various complications if not treated promptly. Long-term episodes of acute or subacute cholecystitis may lead to chronic cholecystitis disease. Gallbladder stones are the main cause of chronic cholecystitis. Stones can lead to repeated obstruction of the gallbladder duct, causing damage to the gallbladder mucosa, resulting in recurrent inflammatory responses in the gallbladder wall, scar formation, and gallbladder dysfunction [21]. Chronic nonlithiatic cholecystitis is mainly caused by bacterial infections of enteric origin, where intestinal bacteria can pass through the bile duct to the gallbladder, or through the blood or lymphatic route to the gallbladder [22]. The treatment of patients with

| Table 1: Comparison of baseline characteristics (\( \bar{x} \pm s \)). |
|-----------------|----------------|------------------------|---------------------|----------------|-----------------|-----------------|
| Groups          | n              | Gender (male/ female)  | Age (year)          | Mean age (year)  | Duration of disease (year) | Stone diameter (cm) | Mean diameter (cm) |
| Study group     | 54             | 28/26                  | 58–77               | 59.23 ± 3.78     | 1–5                         | 2.87–18.67         | 5.23 ± 2.17      |
| Control group   | 54             | 27/27                  | 55–79               | 59.18 ± 4.05     | 1–5                         | 3.25–20.02         | 5.48 ± 1.99      |
| t value         | —              | —                      | —                   | 0.066            | —                           | 1.124             | 0.624            |
| P value         | —              | —                      | —                   | 0.948            | —                           | 0.264             | 0.534            |

| Table 2: Comparison of surgical conditions (\( \bar{x} \pm s \)). |
|-----------------|----------------|------------------------|---------------------|----------------|-----------------|-----------------|
| Groups          | n              | Duration of surgery (min) | Intraoperative bleeding volume (ml) | Time to first post-operative bowel movement (h) | Postoperative hospital stay (d) |
| Study group     | 54             | 88.25 ± 25.63           | 75.83 ± 7.23         | 37.85 ± 3.17     | 5.02 ± 3.21     |
| Control group   | 54             | 120.98 ± 31.65          | 119.16 ± 14.41       | 58.25 ± 5.21     | 8.74 ± 3.11     |
| t value         | —              | —                      | —                   | < 0.001          | < 0.001         |
| P value         | —              | —                      | —                   | < 0.001          | < 0.001         |
gallbladder and liver in a close relationship, often accompanied by liver qi stagnation, liver and gallbladder dampness, and heat, stasis, and blood blockage [30]. Drugs such as Chai Hu to clear the liver, Yu Jin to clear heat and dampness, Chuan Xiong to activate blood circulation and remove blood stasis, Qian Cao and Cang Zhu to clear heat and dampness, and heat, stasis, and blood blockage [30]. Drugs such as Chai Hu to clear the liver, Yu Jin to clear heat and dampness, Chuan Xiong to activate blood circulation and remove blood stasis, Qian Cao and Cang Zhu to clear heat and dampness, Bai Shaoyao to soften the liver and relieve pain, Yuan Hu Suo to move Qi and blood to relieve pain, Hai Jin Sha to clear heat and dampness, and drain stones, and Citrus Aurantium to incorporate and move Qi to facilitate the draining of

Table 3: Comparison of inflammatory factors levels (X ± s).

| Groups  | n  | CRP (mg/L) Before treatment | After treatment | IL-6 (mg/L) Before treatment | After treatment | IL-8 (mg/L) Before treatment | After treatment |
|---------|----|-----------------------------|----------------|-------------------------------|----------------|-------------------------------|----------------|
| Study group | 54 | 6.25 ± 1.98                 | 16.18 ± 3.21   | 46.21 ± 5.34                  | 55.74 ± 6.18   | 10.17 ± 3.74                  | 22.57 ± 5.67   |
| Control group | 54 | 6.11 ± 2.06                 | 26.24 ± 2.87   | 46.18 ± 5.29                  | 64.87 ± 4.96   | 10.23 ± 3.65                  | 41.68 ± 5.21   |
| t value   |    | 0.360                       | 17.168         | 0.029                         | 8.467          | 0.084                         | 18.237         |
| P value   |    | 0.720                       | < 0.001        | 0.977                         | < 0.001        | 0.933                         | < 0.001        |

Table 4: Comparison of complications (%).

| Groups  | n  | Incisional infection | Bile duct bleeding | Abdominal infection | Pulmonary infection | Intrahepatic cholestasis | Incidence |
|---------|----|----------------------|--------------------|---------------------|---------------------|--------------------------|-----------|
| Study group | 54 | 1 (1.85)             | 1 (1.85)           | 0 (0.00)            | 0 (0.00)            | 1 (1.85)                 | 3 (5.56)  |
| Control group | 54 | 5 (9.25)             | 2 (3.71)           | 1 (1.85)            | 1 (1.85)            | 4 (7.41)                 | 13 (24.07) |
| x² value |    | —                    | —                  | —                   | —                   | —                        | 7.337     |
| P value  |    | —                    | —                  | —                   | —                   | —                        | 0.007     |

Table 5: Comparison of quality of life (X ± s).

| Groups  | n  | Physical function | Psychological function | Social function |
|---------|----|-------------------|------------------------|-----------------|
| Study group | 54 | 86.23 ± 5.96      | 87.45 ± 5.12           | 83.17 ± 4.91    |
| Control group | 54 | 73.84 ± 5.17      | 76.77 ± 4.84           | 73.65 ± 5.95    |
| t value   |    | 11.540            | 11.139                 | 9.069           |
| P value   |    | < 0.001           | < 0.001                | < 0.001         |

The results of this study showed that laparoscopic cholecystectomy was associated with shorter operative time, intraoperative bleeding, time to first postoperative bowel movement, and shorter postoperative hospital stay compared to open cholecystectomy (P < 0.05), suggesting the advantages of laparoscopic cholecystectomy. This was attributed to the clear laparoscopic view of the gallbladder surface and surrounding tissues. The clear surgical view combined with advanced endoscopic equipment maximizes the noninvasive nature of the human tissue and speeds up postoperative recovery. The patients given laparoscopic cholecystectomy showed lower levels of CRP, IL-6, and IL-8 versus those given open cholecystectomy (P < 0.05), indicating that laparoscopic cholecystectomy results in less trauma and a milder inflammatory response. The reason for this is that open cholecystectomy is highly invasive and has a greater impact on the patient’s tissues, endocrine system, and associated cytokines, whereas laparoscopic cholecystectomy has a small surgical incision, a low incidence of bile duct injury, and a low incidence of bile leakage from the stump. The gallbladder duct is delayed, and there is less postoperative intraabdominal bleeding and less interference with organ function. In addition, laparoscopic cholecystectomy had a significantly lower complication rate and a significantly higher quality of life score compared to open cholecystectomy (P < 0.05). The cure rate of laparoscopic cholecystectomy exceeded 98%, with no absolute contraindications, small surgical incisions, and rapid postoperative recovery, reducing the incidence of postoperative complications and improving the quality of life of patients. Investigated the clinical efficacy of laparoscopic cholecystectomy versus open cholecystectomy and found that laparoscopic cholecystectomy is characterized by less trauma, less body impact, and faster postoperative recovery versus open cholecystectomy, which is consistent with the results of the present study.

Chronic cholecystitis belongs to the category of hypochondriac pain in TCM, with the disease located in the gallbladder and liver in a close relationship, often accompanied by liver qi stagnation, liver and gallbladder dampness and heat, stasis, and blood blockage [30]. Drugs such as Chai Hu to clear the liver, Yu Jin to clear heat and dampness, Chuan Xiong to activate blood circulation and remove blood stasis, Qian Cao and Cang Zhu to clear heat and dampness, Bai Shao to soften the liver and relieve pain, Yuan Hu Suo to move Qi and blood to relieve pain, Hai Jin Sha to clear heat and dampness, and drain stones, and Citrus Aurantium to broaden the middle and move Qi to facilitate the draining of...
liver Qi [31]. Different prescriptions should be used according to the type of Chinese medicine, and it should be emphasized that in the actual symptoms of chronic cholecystitis, the main focus is on eliminating evil, such as clearing heat and dampness, soothing the liver and bile, and moving Qi and invigorating blood, while in the deficiency symptoms, the main focus is on helping the righteous, such as strengthening the spleen and benefiting Qi, nourishing Yin and softening the liver, and can also be combined with Chinese medicine specialties, such as acupuncture and moxibustion ear points, medication paste on the abdomen, and acupoint burial [30–32].

But our experiments still have limitations. First of all, we need long-term regular follow-up visits to determine the prognostic effect. Second, we need to expand the scope of the trial and the sample size. Although sensitive and responsive instruments exist for measuring the quality of life after cholecystectomy, more research is needed to identify modifications that may lead to significant improvements.

5. Conclusion
To sum up, laparoscopic cholecystectomy provides better surgical results, mitigates the inflammatory response, lowers the incidence of complications, and improves the quality of life of patients versus open cholecystectomy, so it is worthy of application in clinical treatment.

Data Availability
All data generated or analysed during this study are included in this published article.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] M. W. Jones, E. Guay, and J. G. Deppen, “Chronic cholecystitis,” in StatPearlsStatPearls Publishing LLC, Tampa, FL, USA, 2022.
[2] G. Zhong, Y. Luo, Z. Chi et al., “Clinical acupuncture therapy for chronic cholecystitis: a protocol for systematic review and meta-analysis,” Medicine, vol. 100, no. 10, Article ID e24994, 2021.
[3] D. Schottenfeld and J. Beebe-Dimmer, “Chronic inflammation: a common and important factor in the pathogenesis of neoplasia,” CA: A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 69–83, 2006.
[4] L. M. Knab, A. M. Boller, and D. M. Mahvi, “Cholecystitis,” Surgical Clinics of North America, vol. 94, no. 2, pp. 455–470, 2014.
[5] F. Lammert, K. Gurusamy, C. W. Ko et al., “Gallstones,” Nature Reviews Disease Primers, vol. 2, no. 1, Article ID 16024, 2016.
[6] H. Mirali, I. Kamaoui, T. El Harroudi, I. Skiker, and B. Serji, “Giant gallbladder revealed by chronic cholecystitis gallstone: a case report and review of the literature,” Cureus, vol. 13, no. 3, Article ID e13906, 2021.
[7] I. N. Grigore’eva and T. I. Romanova, “Gallstone disease and microbiome,” Microorganisms, vol. 8, no. 6, p. 835, 2020.
[8] K. R. Hassler, “Laparoscopic cholecystectomy,” in StatPearlsStatPearls Publishing LLC, Tampa, FL, USA, 2022.
[9] G. E. Njeze, “Gallstones,” Nigerian Journal of Surgery, vol. 19, no. 2, pp. 49–55, 2013.
[10] M. F. L. Guarino, S. Cocca, A. Altomare, S. Emerenziani, and M. Cicala, “Ursoodeoxycholic acid therapy in gallbladder disease, a story not yet completed,” World Journal of Gastroenterology, vol. 19, no. 31, p. 5029, 2013.
[11] I. J. Beckingham, “ABC of diseases of liver, pancreas, and biliary system: gallstone disease,” BMJ, vol. 322, no. 7278, pp. 91–94, 2001, Jan 13.
[12] J. M. Nesland, “Chronic cholecystitis,” Ultrastructural Pathology, vol. 28, no. 3, p. 121, 2004.
[13] J. Morales-Maza, J. Rodriguez-Quintero, O. Santes et al., “Conversion from laparoscopic to open cholecystectomy: risk factor analysis based on clinical, laboratory, and ultrasound parameters,” Revista de Gastroenterología de México, vol. 86, no. 4, pp. 363–369, 2021.
[14] R. Rio-Tinto and J. Canena, “Endoscopic treatment of post-cholecystectomy biliary leaks,” GE Portugaise Journal of Gastroenterology, vol. 28, no. 4, pp. 265–273, 2021.
[15] C. Dekonenko and G. W. Holcomb, “Laparoscopic cholecystectomy in children,” Journal of Laparoendoscopic & Advanced Surgical Techniques, vol. 31, no. 10, pp. 1180–1184, 2021.
[16] R. T. A. Padbury, “Day-only laparoscopic cholecystectomy in 2021,” ANZ Journal of Surgery, vol. 91, no. 4, p. 484, 2021.
[17] E. Reitano, N. deAngelis, E. Schembri et al., “Learning curve for laparoscopic cholecystectomy has not been defined: a systematic review,” ANZ Journal of Surgery, vol. 91, no. 9, pp. E554–e560, 2021.
[18] M. Hirota, T. Takada, Y. Kawarada et al., “Diagnostic criteria and severity assessment of acute cholecystitis: tokyo guidelines,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 14, no. 1, pp. 78–82, 2007.
[19] H. Muaddi, M. E. Hafid, W. J. Choi et al., “Clinical outcomes of robotic surgery compared to conventional surgical approaches (laparoscopic or open): a systematic overview of reviews,” Annals of Surgery, vol. 273, no. 3, pp. 467–473, 2021.
[20] N. P. F. Pequeno, N. L. d A. Cabral, D. M. Marchioni, S. C. V. C. Lima, and C. d O. Lyra, “Quality of life assessment instruments for adults: a systematic review of population-based studies,” Health and Quality of Life Outcomes, vol. 18, no. 1, p. 208, 2020.
[21] R. C. Mahoney, S. R. Marisone Jr., A. D. Marumoto, and D. E. Hemmings, “Enormous gallstone discovered in the setting of acute-on-chronic cholecystitis,” Hawaii Journal of Health & Social Welfare, vol. 80, pp. 38–40, 2021.
[22] G. Gonzalez-Escobedo, J. M. Marshall, and J. S. Gunn, “Chronic and acute infection of the gall bladder by salmonella typhi: understanding the carrier state,” Nature Reviews Microbiology, vol. 9, no. 1, pp. 9–14, 2011.
[23] M. W. Jones, E. Guay, and J. G. Deppen, “Open cholecystectomy,” in StatPearlsStatPearls Publishing LLC, Tampa, FL, USA, 2022.
[24] M. Riccardi, M. Dughayli, and F. Baidoun, “Open cholecystectomy,” in StatPearlsStatPearls Publishing LLC, Tampa, FL, USA, 2022.
[25] S. Mallappa and R. Soobrah, “Laparoscopic cholecystectomy: evaluation of web-based information,” Cureus, vol. 14, no. 1, Article ID e20897, 2022.
[26] V. Gupta, “Landmarking for safe laparoscopic cholecystectomy,” International Hepato-Pancreato-Biliary Association, vol. 23, no. 7, p. 1137, 2021.
[27] M. Vannucci, G. G. Laracca, P. Mercantini et al., "Statistical models to preoperatively predict operative difficulty in laparoscopic cholecystectomy: a systematic review," *Surgery*, vol. 171, 2021.

[28] I. Kurtulus, O. D. Culcu, and M. S. Degerli, "Which is more effective: laparoscopic or open partial cholecystectomy?" *Journal of Laparoendoscopic & Advanced Surgical Techniques*, vol. 32, no. 5, pp. 476–484, 2022.

[29] A. Kannan, A. Tara, H. Quadir et al., "The outcomes of the patients undergoing harmonic scalpel laparoscopic cholecystectomy," *Cureus*, vol. 13, no. 6, Article ID e15622, 2021.

[30] Y. Zhu, H. Xu, M. Song et al., "Acupuncture treatment of chronic cholecystitis using acupoints," *Traditional Chinese Medicine*, vol. 7, p. 332, 2018.

[31] J. J. Li, Q. Liang, and G. C. Sun, "Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition," *Journal of Integrative Medicine*, vol. 19, no. 6, pp. 469–477, 2021.

[32] L. Pan, J. Gao, Y. Han et al., "The treatment of cholecystitis and cholelithiasis by Tibetan medicine," *Evidence-Based Complementary and Alternative Medicine*, vol. 2021, Article ID 9502609, 21 pages, 2021.